Evidence map›Paper›PMID 39545419›Full record

ArticleThe Journal of clinical investigation2024

CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.

Paul Deschamps, Margaux Wacheux, Axel Gosseye, Margot Morabito, Arnaud Pagès, Anne-Marie Lyne, Alexia Alfaro, Philippe Rameau, Aygun Imanci, Rabie Chelbi and 20 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Paul DeschampsINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Margaux WacheuxINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Axel GosseyeINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Margot MorabitoINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Arnaud PagèsINSERM U1018, Gustave Roussy Cancer Center, Villejuif, France.
Anne-Marie LyneInstitut Curie, PSL Research University, Paris, France.
Alexia AlfaroINSERM US23, CNRS UAR 3655, Gustave Roussy Cancer Center, Villejuif, France.
Philippe RameauINSERM US23, CNRS UAR 3655, Gustave Roussy Cancer Center, Villejuif, France.
Aygun ImanciINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Rabie ChelbiINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Valentine MarchandINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Aline RennevilleINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Valerie LapierreCellular Therapy Department, Gustave Roussy Cancer Center, Villejuif, France.
Bouchra BadaouiDepartment of Hematology and Immunology, Henri-Mondor Hospital, AP-HP, Créteil, France.
Orianne Wagner-BallonDepartment of Hematology and Immunology, Henri-Mondor Hospital, AP-HP, Créteil, France.
Céline BerthonClinical Hematology Department, University Hospital, Lille, France.
Thorsten BraunClinical Hematology Department, Hôpital Avicenne, Bobigny, France.
Christophe WillekensINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Raphael ItzyksonAdult Hematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Pierre FenauxAdult Hematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sylvain ThépotClinical Hematology Department, University Hospital, Angers, France.
Gabriel EtienneClinical Hematology Department, Institut Bergonié, Bordeaux, France.
Emilie Elvira-MatelotINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Francoise PorteuINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Nathalie DroinINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Leïla PeriéInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico-Chimie Curie, Paris, France.
Lucie LaplaneINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Eric SolaryINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Dorothée Selimoglu-BuetINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy with limited therapeutic options. Single-cell analysis of clonal architecture demonstrates early clonal dominance with few residual WT hematopoietic stem cells. Circulating myeloid cells of the leukemic clone and the cytokines they produce generate a deleterious inflammatory climate. Our hypothesis is that therapeutic control of the inflammatory component in CMML could contribute to stepping down disease progression. The present study explored the contribution of immature granulocytes (iGRANs) to CMML progression. iGRANs were detected and quantified in the peripheral blood of patients by spectral and conventional flow cytometry. Their accumulation was a potent and independent poor prognostic factor. These cells belong to the leukemic clone and behaved as myeloid-derived suppressor cells. Bulk and single-cell RNA-Seq revealed a proinflammatory status of iGRAN that secreted multiple cytokines of which CXCL8 was at the highest level. This cytokine inhibited the proliferation of WT but not CMML hematopoietic stem and progenitor cells (HSPCs) in which CXCL8 receptors were downregulated. CXCL8 receptor inhibitors and CXCL8 blockade restored WT HSPC proliferation, suggesting that relieving CXCL8 selective pressure on WT HSPCs is a potential strategy to slow CMML progression and restore some healthy hematopoiesis.

Indexed as

HematopoiesisInterleukin-8Leukemia, Myelomonocytic, ChronicAgedFemaleGranulocytesHematopoietic Stem CellsHumansMaleMiddle AgedMyeloid-Derived Suppressor CellsCXCL8 protein, humanInterleukin-8CytokinesHematologyLeukemiasNeutrophils

Identifiers

PMID39545419
PMCPMC11563679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.